Sign In
Buy STIM
$1.20
-0.0300 (-2.44%)
At Close: Jun 22, 2026
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
04:40pm, Wednesday, 28'th Sep 2022 Benzinga
Gainers
Prothena Corporation plc (NASDAQ: PRTA) shares climbed 76.4% to $54.54 after Biogen and Eisai Co. Ltd. announced late Tuesday positive results from a late-stage study of their Alzheimer’s
Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
12:31pm, Monday, 26'th Sep 2022 GlobeNewswire Inc.
Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need of treatment Upgrades will enhance and automa
Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony
12:33pm, Tuesday, 13'th Sep 2022 GlobeNewswire Inc.
The state-of-the-art training center is the first of its kind to further best practices with transformative NeuroStar Advanced Therapy for Mental Health The state-of-the-art training center is the fir
Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health
12:30pm, Monday, 29'th Aug 2022 GlobeNewswire Inc.
Latest NeuroStar innovation to simplify the motor threshold determination for clinicians Latest NeuroStar innovation to simplify the motor threshold determination for clinicians
Despite Competition This Analyst Finds BrainsWay Attractive
06:50pm, Thursday, 11'th Aug 2022 Benzinga
Yesterday BrainsWay Ltd (NASDAQ: BWAY) reported Q2 sales of $8.0 million, up 14% Y/Y, missing the consensus of $8.47 million, amid a slowdown in capital equipment orders, particularly in the U.S.
R
Neuronetics (STIM) Just Flashed Golden Cross Signal: Do You Buy?
01:55pm, Monday, 08'th Aug 2022 Zacks Investment Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:30pm, Friday, 05'th Aug 2022 GlobeNewswire Inc.
MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve
Neuronetics, Inc. (STIM) Q2 2022 Earnings Call Transcript
02:30am, Wednesday, 03'rd Aug 2022 The Motley Fool
STIM earnings call for the period ending June 30, 2022.
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
01:15pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 6.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics Inc (STIM) CEO Keith Sullivan on Q2 2022 Results - Earnings Call Transcript
12:52pm, Tuesday, 02'nd Aug 2022
Neuronetics Inc (NASDAQ:STIM ) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & CEO Steve Furlong - SVP,
Neuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference
08:30pm, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
MALVERN, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve
Neuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference
04:30pm, Thursday, 28'th Jul 2022
MALVERN, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve th
Neuronetics and Alleviant Health Centers Announce Exclusive Partnership
12:31pm, Monday, 25'th Jul 2022 GlobeNewswire Inc.
Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients
Neuronetics to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call
12:30pm, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
MALVERN, Pa., July 19, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression
11:00am, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
Indication demonstrates NeuroStar TMS safety and efficacy in improving anxiety symptoms in depressed patients Indication demonstrates NeuroStar TMS safety and efficacy in improving anxiety symptoms in
